<?xml version='1.0' encoding='utf-8'?>
<document id="25616988"><sentence text="Validated LC-MS/MS Assay for the Quantitative Determination of Fimasartan in Human Plasma: Application to Pharmacokinetic Studies."><entity charOffset="63-73" id="DDI-PubMed.25616988.s1.e0" text="Fimasartan" /></sentence><sentence text="A simple, rapid and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the quantification of a newly developed antihypertensive agent fimasartan (BR-A657, Kanarb(®)) in human plasma was developed and validated"><entity charOffset="162-172" id="DDI-PubMed.25616988.s2.e0" text="fimasartan" /></sentence><sentence text=" Fimasartan and internal standard (IS, BR-A563) were extracted by simple protein precipitation using acetonitrile and separated on a Phenyl-Hexyl column (Luna(®), 5 µm, 50 mm × 2"><entity charOffset="1-11" id="DDI-PubMed.25616988.s3.e0" text="Fimasartan" /><entity charOffset="101-113" id="DDI-PubMed.25616988.s3.e1" text="acetonitrile" /><entity charOffset="133-145" id="DDI-PubMed.25616988.s3.e2" text="Phenyl-Hexyl" /><pair ddi="false" e1="DDI-PubMed.25616988.s3.e0" e2="DDI-PubMed.25616988.s3.e0" /><pair ddi="false" e1="DDI-PubMed.25616988.s3.e0" e2="DDI-PubMed.25616988.s3.e1" /><pair ddi="false" e1="DDI-PubMed.25616988.s3.e0" e2="DDI-PubMed.25616988.s3.e2" /><pair ddi="false" e1="DDI-PubMed.25616988.s3.e1" e2="DDI-PubMed.25616988.s3.e1" /><pair ddi="false" e1="DDI-PubMed.25616988.s3.e1" e2="DDI-PubMed.25616988.s3.e2" /></sentence><sentence text="0 mm, Phenomenex) under the gradient conditions of mobile phase A (distilled water with 0" /><sentence text="1% formic acid) and mobile phase B (100% acetonitrile with 0"><entity charOffset="3-14" id="DDI-PubMed.25616988.s5.e0" text="formic acid" /><entity charOffset="41-53" id="DDI-PubMed.25616988.s5.e1" text="acetonitrile" /><pair ddi="false" e1="DDI-PubMed.25616988.s5.e0" e2="DDI-PubMed.25616988.s5.e0" /><pair ddi="false" e1="DDI-PubMed.25616988.s5.e0" e2="DDI-PubMed.25616988.s5.e1" /></sentence><sentence text="1% formic acid) at a flow rate of 0"><entity charOffset="3-14" id="DDI-PubMed.25616988.s6.e0" text="formic acid" /></sentence><sentence text="25 mL/min" /><sentence text=" Detection and quantification were performed by the mass spectrometer using multiple reaction monitoring mode at m/z 500" /><sentence text="2 → 221" /><sentence text="2 for fimasartan and m/z 524"><entity charOffset="6-16" id="DDI-PubMed.25616988.s10.e0" text="fimasartan" /></sentence><sentence text="3 → 204" /><sentence text="9 for the IS" /><sentence text=" The assay was linear over a calibration range of 0" /><sentence text="5-500 ng/mL with a lower limit of quantification of 0" /><sentence text="5 ng/mL" /><sentence text=" The coefficient of variation of this assay precision was &lt;14" /><sentence text="9% and the accuracy exceeded 91" /><sentence text="9%" /><sentence text=" This method provided the necessary sensitivity, linearity, precision, accuracy and specificity to allow the determination of fimasartan after oral administration to healthy Korean male volunteers in several drug-drug interaction studies conducted at the Clinical Trials Center of Seoul National University Hospital"><entity charOffset="126-136" id="DDI-PubMed.25616988.s19.e0" text="fimasartan" /></sentence><sentence text=" " /></document>